RER1 Stock Chart & Stats
€49.96
€1.00(1.92%)
At close: 4:00 PM EST
€49.96
€1.00(1.92%)
Day’s Range― - ―
52-Week Range€43.42 - €53.70
Previous CloseN/A
Volume500.00
Average Volume (3M)1.00
Market Cap
€10.94B
Enterprise Value€12.60B
Total Cash (Recent Filing)€391.38M
Total Debt (Recent Filing)€2.31B
Price to Earnings (P/E)21.8
Beta0.47
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.43
Shares Outstanding209,125,150
10 Day Avg. Volume1
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio3.24
Price to Book (P/B)5.20
Price to Sales (P/S)3.81
P/FCF Ratio19.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.18
Revenue Forecast (FY)€2.79B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityGross margins of ~68–73%, EBITDA margins of ~30–37%, and net margins of ~17–19% show a profitable operating model. Sustaining these levels across annual periods and TTM should support reinvestment, resilience, and durable earnings generation over the next several quarters.
Strong Cash GenerationFree cash flow was positive in every reported period and reached about €582M TTM, with roughly 30% TTM growth and ~0.84 conversion versus earnings. This cash backing improves capacity to fund operations and investment while reducing reliance on external financing.
Diversified Pharmaceutical PortfolioRecordati combines specialty and primary care medicines, including rare-disease treatments, and sells through its own organizations and selected partners across multiple markets. This breadth can support recurring demand and reduce reliance on a single therapeutic area or geography.
Bears Say
Meaningful LeverageTTM debt-to-equity of ~1.15 indicates leverage remains material despite improvement from ~1.29–1.33 in 2024–2025. This can constrain financial flexibility, increase financing sensitivity, and leave fewer resources available for acquisitions, investment, or shareholder returns.
Cash Flow VariabilityCash generation is positive overall but uneven: 2023 had a notable free cash flow drop, and TTM operating cash flow coverage of ~0.39 was below prior years. Variability and a thinner coverage cushion can make funding less predictable during weaker trading periods.
Margins Below PeakAlthough profitability remains strong, peak profitability was in 2021 and margins have been slightly lower since, with EBITDA and net margins below that peak. Continued moderation would reduce incremental earnings from revenue growth and could limit operating leverage.
Recordati Industria Chimica e Farmaceutica SPA News
RER1 FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
Recordati Industria Chimica e Farmaceutica SPA lowest stock price was €43.42 and its highest was €53.70 in the past 12 months.
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
Recordati Industria Chimica e Farmaceutica SPA’s market cap is €10.94B.
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is Nov 10, 2026 which is in 9 days.
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Recordati Industria Chimica e Farmaceutica SPA released its earnings results on Jul 28, 2026. The company reported €1.292 earnings per share for the quarter.
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Overvalued.
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
Recordati Industria Chimica e Farmaceutica SPA does not currently pay dividends.
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding.
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Recordati Industria Chimica e Farmaceutica SPA reported an EPS of €1.292 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
Currently, no hedge funds are holding shares in DE:RER1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.